Pharmacogenetics and Depression: A Critical Perspective.
Ontology highlight
ABSTRACT: Depression leads the higher personal and socio-economical burden within psychiatric disorders. Despite the fact that over 40 antidepressants (ADs) are available, suboptimal response still poses a major challenge and is thought to be partially a result of genetic variation. Pharmacogenetics studies the effects of genetic variants on treatment outcomes with the aim of providing tailored treatments, thereby maximizing efficacy and tolerability. After two decades of pharmacogenetic research, variants in genes coding for the cytochromes involved in ADs metabolism (CYP2D6 and CYP2C19) are now considered biomarkers with sufficient scientific support for clinical application, despite the lack of conclusive cost/effectiveness evidence. The effect of variants in genes modulating ADs mechanisms of ac
SUBMITTER: Corponi F
PROVIDER: S-EPMC6761796 | biostudies-literature | 2019 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA